AMSilk News

New protein production strain delivers unprecedented yield with greater efficiency and lower costs

AMSilk announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO). Gudrun will be responsible for AMSilk’s protein and strain strategy as well as bridging science and business development.

Don't miss the chance to connect with AMSilk, as we join the panel at SynBioBeta Global Synthetic Biology Conference. The SynBioBeta 2023 event brings together the most innovative pioneers in bioindustrials who are passionate about transforming society and our planet for the better.

AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announced it has successfully raised an additional EUR 25 million in an extended Series C financing led by existing investor ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital.

Creating a better future with biotechnology - this vision is shared by BRAIN Biotech AG (BRAIN Biotech), a leader in the development and manufacture of bio-based solutions and products for industry, and AMSilk GmbH (AMSilk), the world's first industrial supplier of innovative biomaterials for more sustainable applications in the textile, medical and consumer goods industries.

Expanding biotech laboratory, pilot plants and office space, AMSilk embarks on the next stage of its journey to provide biofabricated silk materials across the world.